Video: Risk Management of Adventitious Agent Contamination in Biopharmaceutical Products

February 29, 2012

During this podcast, we will discuss the causes and implications of Adventitious Agent Contamination for pharmaceutical and biopharmaceutical manufacturers. We will discuss ways in which Lancaster Laboratories is helping manufacturers minimize the risk for this contamination to avoid production delays.

During this podcast, we will discuss the causes and implications of Adventitious Agent Contamination for pharmaceutical and biopharmaceutical manufacturers. We will discuss ways in which Lancaster Laboratories is helping manufacturers minimize the risk for this contamination to avoid production delays.

Presenter:
Jeri Ann Boose, Ph.D.
Director, Biopharmaceutical Services
Lancaster Laboratories

Katherine Bergmann, Ph.D.
Manager, Viral Safety and Viral Clearance Services
Lancaster Laboratories

Online Resources:
Register for the Live Web Conference More Information